EIF4A Dependency: the Hidden Key to Unlock KRAS Mutant Non-small Cell Lung Cancer's Vulnerability

Overview

Journal Transl Lung Cancer Res

Date 2024 Jan 11

PMID 38205207

Authors

Silvia Casacuberta-Serra

Inigo Gonzalez-Larreategui

Laura Soucek

Affiliations

Soon will be listed here.

Citing Articles

Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets.

Sehrawat U Int J Mol Sci. 2024; 25(19).

PMID: 39409166 PMC: 11477148. DOI: 10.3390/ijms251910835.

References

Bartish M, Abraham M, Goncalves C, Larsson O, Rolny C, del Rincon S . The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment. Nat Rev Cancer. 2023; 23(6):408-425. DOI: 10.1038/s41568-023-00567-5. View

Wu S, Wagner G . Computational inference of eIF4F complex function and structure in human cancers. Proc Natl Acad Sci U S A. 2024; 121(5):e2313589121. PMC: 10835048. DOI: 10.1073/pnas.2313589121. View

Janne P, Riely G, Gadgeel S, Heist R, Ou S, Pacheco J . Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation. N Engl J Med. 2022; 387(2):120-131. DOI: 10.1056/NEJMoa2204619. View

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

Chanvorachote P, Sriratanasak N, Nonpanya N . C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target. Anticancer Res. 2020; 40(2):609-618. DOI: 10.21873/anticanres.13990. View

Nangia V, Siddiqui F, Caenepeel S, Timonina D, Bilton S, Phan N . Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in -Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2018; 8(12):1598-1613. PMC: 6279543. DOI: 10.1158/2159-8290.CD-18-0277. View

Pelletier J, Graff J, Ruggero D, Sonenberg N . Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015; 75(2):250-63. PMC: 4299928. DOI: 10.1158/0008-5472.CAN-14-2789. View

Di Federico A, Ricciotti I, Favorito V, Michelina S, Scaparone P, Metro G . Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer. Curr Oncol Rep. 2023; 25(9):1017-1029. DOI: 10.1007/s11912-023-01436-y. View

Dy G, Govindan R, Velcheti V, Falchook G, Italiano A, Wolf J . Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023; 41(18):3311-3317. PMC: 10414711. DOI: 10.1200/JCO.22.02524. View

10.

Dempke W . Targeted Therapy for NSCLC--A Double-edged Sword?. Anticancer Res. 2015; 35(5):2503-12. View

11.

Xu Y, Poggio M, Jin H, Shi Z, Forester C, Wang Y . Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019; 25(2):301-311. PMC: 6613562. DOI: 10.1038/s41591-018-0321-2. View

12.

Kayastha F, Herrington N, Kapadia B, Roychowdhury A, Nanaji N, Kellogg G . Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma. Mol Med. 2022; 28(1):101. PMC: 9441068. DOI: 10.1186/s10020-022-00534-0. View

13.

Chmielewska I, Krawczyk P, Grenda A, Wojcik-Superczynska M, Krzyzanowska N, Gil M . Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with Mutations-A Comprehensive Review and Description of Single Site Experience. Cancers (Basel). 2023; 15(14). PMC: 10378665. DOI: 10.3390/cancers15143732. View

14.

Yang Y, Zhang H, Huang S, Chu Q . KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration. J Clin Med. 2023; 12(2). PMC: 9861148. DOI: 10.3390/jcm12020709. View

15.

Doha Z, Sears R . Unraveling MYC's Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance. Pathophysiology. 2023; 30(3):400-419. PMC: 10537413. DOI: 10.3390/pathophysiology30030031. View

16.

Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I . Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015; 14(4):261-78. DOI: 10.1038/nrd4505. View

17.

Farnsworth D, Inoue Y, Johnson F, de Rappard-Yuswack G, Lu D, Shi R . MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. NPJ Precis Oncol. 2022; 6(1):88. PMC: 9684561. DOI: 10.1038/s41698-022-00328-x. View

18.

Del Valle L, Dai L, Lin H, Lin Z, Chen J, Post S . Role of EIF4G1 network in non-small cell lung cancers (NSCLC) cell survival and disease progression. J Cell Mol Med. 2021; 25(6):2795-2805. PMC: 7957206. DOI: 10.1111/jcmm.16307. View

19.

Ruggero D . The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009; 69(23):8839-43. PMC: 2880919. DOI: 10.1158/0008-5472.CAN-09-1970. View

20.

Ernst J, Thompson P, Nilewski C, Sprengeler P, Sperry S, Packard G . Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020; 63(11):5879-5955. DOI: 10.1021/acs.jmedchem.0c00182. View